Immuron Limited is experiencing significant momentum across its therapeutic pipeline, with the Australian biopharmaceutical company reporting record sales and multiple clinical milestones expected throughout 2025. The company is on track to exceed A$7 million in sales this financial year, representing a substantial increase from the previous year's A$4.9 million.
Clinical Development Progress
IMM-124E (Travelan®) for Traveler's Diarrhea
The company's lead therapeutic candidate has reached a critical juncture in its development. All US armed services participants in the Uniformed Services University Travelan® field study have been randomized and deployed, with recruitment completed in March. The final patient visit is anticipated in July 2025, with topline results expected to follow in October 2025.
Following these results, Immuron plans to request an end-of-Phase 2 meeting with the FDA for IMM-124E, which will serve as a precursor to commencing a Phase 3 clinical program. The company hopes this trial will enable Travelan® to be recommended in traveler's diarrhea guidelines, potentially increasing its market potential and enhancing the long-standing relationship with the US Department of Defense.
Based on Lumanity's opportunity assessment prepared for Immuron, the base case yearly revenue in the USA for IMM-124E is projected at US$102 million.
IMM-529 for Clostridioides Difficile Infection
Immuron is progressing with a new Investigational New Drug (IND) application to the FDA to initiate clinical development of IMM-529 for the treatment of Clostridioides difficile infection (CDI) and prevention of CDI recurrence. The company has completed a final draft of the investigational brochure and clinical protocol, with the non-clinical and clinical sections of the IND also largely completed.
The company anticipates IND submission to the FDA in August 2025, with FDA approval serving as a precursor to commencing a Phase 2 clinical program. According to Lumanity's assessment presented at last year's AGM, the IMM-529 market in the US can reach peak revenues of approximately US$400 million.
Addressing Antimicrobial Resistance
IMM-986 for Vancomycin-Resistant Enterococci
Through a research collaboration with Monash University announced in January, Immuron is developing IMM-986, a new therapeutic candidate against vancomycin-resistant enterococci (VRE). VRE antimicrobial resistance poses a significant threat to healthcare systems worldwide, leading to more severe and harder-to-treat infections in healthcare settings such as hospitals and nursing homes.
These infections often result in longer hospital stays, higher medical costs, and increased mortality rates. In the U.S., the estimated national cost to treat these infections exceeds $4.6 billion annually, according to CDC Antimicrobial Resistance Facts and Stats. Immuron anticipates the results of this pre-clinical research to be completed in August 2025.
Product Launch Initiatives
ProIBS® Market Entry
Immuron has entered into an agreement with Calmino to distribute ProIBS® exclusively in Australia and New Zealand. ProIBS® is a European certified medical product for treating symptoms related to irritable bowel syndrome (IBS), including abdominal pain, bloating, and changes in bowel movement such as diarrhea and constipation.
The company has listed ProIBS® in Australia as a complementary medicine and has placed a purchase order with Calmino. Product delivery is anticipated in Q3 2025, with a product launch planned for Q1 2026. The IBS treatment market in Australia is estimated to be part of the broader "Digestives & Intestinal Remedies" market, generating revenue of around A$221 million in 2025, with a projected annual growth rate of 3.28%.
Financial Performance
Immuron achieved record sales through the end of March for the current financial year, marking the highest sales in the company's history. The momentum continued into April during the Easter and ANZAC holiday periods, as well as the spring and summer break in North America, positioning the company to exceed its sales projections for the year.
